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This core set has been approved by the American College of Rheumatology (ACR) Board of Directors as Provisional. This
signifies that the core set has been quantitatively validated using patient data, but it has not undergone validation based
on an external data set. All ACR-approved core sets are expected to undergo intermittent updates.
Objective. To validate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile
dermatomyositis (DM).
Methods. In 2001, a preliminary consensus-derived core set for evaluating response to therapy in juvenile DM was
established. In the present study, the core set was validated through an evidence-based, large-scale data collection that
led to the enrollment of 294 patients from 36 countries. Consecutive patients with active disease were assessed at baseline
and after 6 months. The validation procedures included assessment of feasibility, responsiveness, discriminant and
construct ability, concordance in the evaluation of response to therapy between physicians and parents, redundancy,
internal consistency, and ability to predict a therapeutic response.
Results. The following clinical measures were found to be feasible, and to have good construct validity, discriminative
ability, and internal consistency; furthermore, they were not redundant, proved responsive to clinically important
changes in disease activity, and were associated strongly with treatment outcome and thus were included in the final core
set: 1) physician’s global assessment of disease activity, 2) muscle strength, 3) global disease activity measure, 4) parent’s
global assessment of patient’s well-being, 5) functional ability, and 6) health-related quality of life.
Conclusion. The members of the Paediatric Rheumatology International Trials Organisation, with the endorsement of the
American College of Rheumatology and the European League Against Rheumatism, propose a core set of criteria for the
evaluation of response to therapy that is scientifically and clinically relevant and statistically validated. The core set will
help standardize the conduct and reporting of clinical trials and assist practitioners in deciding whether a child with
juvenile DM has responded adequately to therapy.
INTRODUCTION
Juvenile dermatomyositis (DM) is a multisystem inflam-
matory disease that affects primarily the skin and muscles.
It is the most common of the juvenile idiopathic inflam-
matory myopathies (IIM), with an annual incidence of 2–4
cases per million children (1,2). Although recent series
have documented a marked improvement in long-term
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outcome and survival of juvenile DM patients (3–5), dis-
ease treatment remains largely empiric. One of the leading
factors that has hampered a rational therapeutic approach
to juvenile DM is the lack of standardized and validated
measures for assessing the response to therapy (6). This
deficiency leads to an inability to accurately evaluate or
compare the effectiveness of drug therapies. Recently, the
International Myositis Outcome Assessment and Clinical
Studies (IMACS) group proposed a core set of outcome
measures for inclusion in clinical trials in adult and juve-
nile IIM and defined the degree of change in each core set
measure that is clinically meaningful (7–9); however, until
now these proposals have not yet been formally validated
in prospective studies or clinical trials.
In recent years, the Paediatric Rheumatology Interna-
tional Trials Organisation (PRINTO) (10), in collaboration
with the Pediatric Rheumatology Collaborative Study
Group (PRCSG), and with the support of the European
Union and the US National Institutes of Health, undertook
a multinational effort that aimed to develop and validate a
core set of outcome measures and a definition of clinical
improvement in patients with juvenile DM, similar to that
already done for juvenile idiopathic arthritis (11–13) and
for juvenile systemic lupus erythematosus (14,15).
The results of the first part of the study, published pre-
viously (16), led to the definition of a preliminary consen-
sus-based core set of domains. Here, we report the results
of the second phase of the project, which was aimed at
formally validating the preliminary juvenile DM core set
for the evaluation of response to therapy through a pro-
spective, large-scale data collection process. Our objective
was to further define and validate the preliminary core set
to evaluate the response to therapy in patients with juve-
nile DM.
PATIENTS AND METHODS
Study design. Enrollment began in June 2001 and ended
in March 2004. The participating PRINTO/PRCSG mem-
bers were asked to assess all variables in the preliminary
core set, in all patients seen consecutively in their units
who had probable or definite diagnosis of juvenile DM
(classic DM rash plus at least 2 or 3 of the other Bohan and
Peter criteria, respectively [17,18]), were younger than age
18 years, and were experiencing an active phase of their
disease, defined as either the need to start corticosteroid
therapy and/or a new immunosuppressive medication or,
in those receiving ongoing therapy, the need to undergo a
major increase in the dosage of corticosteroid and/or im-
munosuppressive drugs. Six months after the baseline
evaluation, the core set variables were reassessed in each
patient. We chose this protocol and timeframe to approx-
imate what is usually done in a clinical trial. Patients were
excluded from the study if at baseline, they were experi-
encing drug-induced or spontaneous clinical remission,
were receiving stable therapy, or had a concomitant seri-
ous illness.
In each center, written or verbal informed consent was
obtained from a parent or legal guardian, according to the
requirements of the local ethic committees.
Assessment of preliminary core set variables. The fol-
lowing preliminary core set measures were assessed at
baseline and 6 months later: 1) the physician’s global
assessment of the patient’s overall disease activity on a
10-cm visual analog scale (VAS) (where 0  no activity
and 10  maximum activity) (19); 2) muscle strength via
the Childhood Myositis Assessment Scale (CMAS) (where
0  worst and 52  best) (20–22) and manual muscle
testing (MMT) on 8 muscles tested unilaterally (where 0 
worst and 80  best) (23); 3) serum muscle enzymes (cre-
atine kinase [CK], lactate dehydrogenase, aldolase, aspar-
tate aminotransferase, and alanine aminotransferase) (24–
28), whose results were standardized based on the normal
values provided by each local laboratory as previously
described (14); 4) functional ability via the Childhood
Health Assessment Questionnaire (C-HAQ) (where 0 
best and 3  worst) (29,30); 5) the parent’s global assess-
ment of the patient’s overall well-being on a 10-cm VAS
(where 0  very well and 10  very poor) (19,29,30); 6)
global assessment of disease activity according to the Dis-
ease Activity Score (DAS) (31) and the Myositis Disease
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Activity Assessment (MDAA) (32). Briefly, the DAS is a
20-point scale comprising 2 subscales reflecting skin in-
volvement (ranging from 0 to 9) and muscle inflammation
(ranging from 0 to 11), with higher scores indicating
greater disease activity. The MDAA combines 2 partially
overlapping tools, the Myositis Disease Activity Assess-
ment Visual Analog Scale (MYOACT) and Myositis Intent-
to-Treat Activity Index (MITAX), A-E version. The
MYOACT is composed of a series of 10-cm VAS that refer
to disease activity in the following organs or systems:
constitutional, cutaneous, skeletal, gastrointestinal, pul-
monary, cardiac, other, extraskeletal, muscle, and global.
The MITAX assesses disease activity in the same organs or
systems and is based on the principle of the physician’s
intent-to-treat analysis (33); each organ or system is graded
from A to E depending on the level of disease activity and
therapy administered to the patient. The final preliminary
core set measure 7) health-related quality of life was as-
sessed via the parent’s version of the Child Health Ques-
tionnaire (CHQ) (30,34). Briefly, the CHQ includes 15 sub-
scales and 2 summary measures, the physical health score
(PhS) and the psychosocial health score (PsS). Higher
scores in the scales indicate better health-related quality of
life. The parent’s versions of both the C-HAQ and the CHQ
have been translated and validated in all the languages of
the participating countries (30).
Validation procedures. Validation of the core set mea-
sures was conducted with the use of the Outcome Mea-
sures in Rheumatology Clinical Trials (OMERACT) group
filter for outcome measures in rheumatology (35,36). The
feasibility or practicality of the measures was determined
by addressing the issues of brevity, simplicity, ease of
scoring, and percentage of missing values. Face and con-
tent validity were based on the results of the previous
consensus conference (16). Responsiveness was examined
by determining the ability of each variable to detect clin-
ically important change between baseline and 6 months,
and was measured using the standardized response mean
(SRM). The SRM was calculated as the absolute mean
change in score divided by the SD of that score; 95%
confidence intervals (95% CIs) were also provided (37,38).
An SRM value 0.5 is considered a small effect, values
between 0.5 and 0.8 represent a moderate effect, and
values 0.8 represent a large effect (39,40). The SRM is
calculated in the patients who improved or did not im-
prove using the physician’s judgment of response to ther-
apy as an external marker of change as described below.
Discriminative ability was assessed by evaluating the
ability to discriminate patients who experienced improve-
ment from those who did not, based on physician’s and
parent’s judgment. Physicians and parents were asked to
judge whether the patient’s disease had improved, was
stable, or had worsened at the current assessment com-
pared with the baseline evaluation. In order to make the
physician’s evaluation of disease activity independent
from the physician’s evaluation of response to therapy, the
evaluations where done by 2 observers each one of whom
was blinded to the assessment done by the other. Patients
who were judged as improving were compared with those
who were judged as not improving (i.e., disease remained
stable or worsened) by t-test or the Mann-Whitney U test,
as appropriate. Moreover, the level of concordance be-
tween physicians and parents in the evaluation of re-
sponse to therapy was assessed with the kappa statistic
(41), using the threshold proposed by Landis and Koch
(42).
Convergent construct validity, which is a form of vali-
dation that seeks to examine whether the construct in
question is related to other measures in a manner consis-
tent with a priori prediction, was also investigated. As a
surrogate measure, we chose the physician’s global assess-
ment of the patient’s overall disease activity by Spear-
man’s rank correlation (where a value of 0.7 was consid-
ered high, a value of 0.4–0.7 was moderate, and a value of
0.4 was low). We predicted that correlation of the under-
lying construct of response to therapy with the surrogate
gold standard measure would be in the moderate range,
and thus would provide a different perspective and avoid
redundancy. The issue of colinearity (or redundancy) of
variables was investigated by means of Spearman’s corre-
lation coefficient; a coefficient 0.7 was considered to
represent evidence of collinearity.
The internal consistency of the various scales was de-
termined by Cronbach’s alpha (43) on values at baseline
visit, with the following cutoffs: 0.6  poor, 0.6–0.64 
slight, 0.65–0.69  fair, 0.7–0.79  moderate, 0.8–0.89 
substantial, and 0.9  almost perfect. We anticipated
that a slight/fair Cronbach’s alpha would be sufficient to
demonstrate the internal consistency of the core set dem-
onstrating the ability of the variables of the core set to
“hold together” to measure the underlying construct of
response to therapy (14).
Finally, the association between the 6 core measures and
response to therapy as judged by the attending physician
was evaluated through a multivariate logistic regression
analysis, after having dichotomized the core set measures
according to the best cutoffs obtained from the receiver
operating characteristic curve analysis (44). Determination
of the best cutoffs for each core set variable will help
physicians to decide whether a patient has improved
based on the absolute change in that particular measure.
Data were entered in an Access XP database and ana-
lyzed by 2 of the authors (NR and AP) with Excel XP
(Microsoft, Redmond, WA), XLSTAT-Pro 6.1.9 software
(Addinsoft, Brooklyn, NY), Statistica 6.0 software (Stat-
Soft, Tulsa, OK), and Stata version 7.0 software (Stata,
College Station, TX).
RESULTS
Demographic characteristics. A total of 294 patients
were enrolled from 97 centers in 36 countries as follows:
Argentina (n  35), Australia (n  2), Austria (n  2),
Belgium (n  3), Brazil (n  28), Bulgaria (n  3), Canada
(n  3), Chile (n  3), Costa Rica (n  7), Croatia (n  5),
Cuba (n  1), Czech Republic (n  5), Denmark (n  3),
Finland (n  2), France (n  11), Germany (n  20), Greece
(n  6), Hungary (n  1), Israel (n  4), Italy (n  33),
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Latvia (n  3), Mexico (n  3), The Netherlands (n  17),
Norway (n  5), Poland (n  4), Portugal (n  6), Serbia
and Montenegro (n  6), Singapore (n  1), Slovakia (n 
3), Slovenia (n  1), Spain (n  10), Sweden (n  2),
Switzerland (n  11), Turkey (n  6), the UK (n  24), and
the US (n  15).
Of the 294 patients enrolled, 19 were excluded from the
study; 9 of these patients had polymyositis without cuta-
neous manifestations, 1 patient was later diagnosed as
having muscular dystrophy, and 9 patients were lost to
followup. Of the 275 (94%) patients who completed both
the baseline and 6-month assessments, 168 (61%) were
female and 107 (39%) male; the median age at disease
onset was 7.2 years (interquartile range [IQR] 4.3, 10.2),
and the median disease duration at baseline was 0.6 years
(IQR 0.2, 2.1).
With regard to treatment at baseline assessment, 191
(69%) patients were newly started with pulse or oral cor-
ticosteroid therapy, 38 (14%) had begun therapy with new
immunosuppressive drugs, and 30 (11%) patients had
their dosages of previous therapies increased. A subgroup
of 111 (40%) patients received newly started corticoste-
roids in combination with newly started immunosuppres-
sive drugs.
Feasibility and responsiveness. Table 1 shows the char-
acteristics of each clinical variable. The frequency of miss-
ing data was uniformly 10%, with the exception of CHQ
(19%) and aldolase (36%), demonstrating that all variables
had excellent feasibility. At baseline, patients had, on
average, a high level of disease activity, as shown by the
high median values of the physician’s and parent’s global
assessment and that of the DAS, and by the low median
values of both the CMAS and the MMT. The SRM calcu-
lated for the subgroup of patients who responded to treat-
ment are shown in Table 1. Good responsiveness to clini-
cal change (SRM 0.8) was demonstrated by the 2 global
disease activity tools (with the DAS being superior to both
the MITAX and the MYOACT), the physician’s and par-
ent’s global assessment, the CMAS, the MMT, the physi-
cian’s global assessment of muscle activity, the C-HAQ,
the physical summary score of the health-related quality of
life tool (CHQ PhS), and the parent’s global assessment of
the child’s pain. All other variables showed moderate re-
Table 1. Descriptive characteristics of the variables*
Variable
Sample




Physician’s global assessment of patient’s
overall disease activity (0–10-cm scale) 1
268 5.5 (3.5, 7.2) 1 (0.3, 2.6) 79 (94, 41.9) 1.6 (1.4–1.8)
Parent’s global assessment of patient’s overall
well-being (0–10-cm scale) 1
255 5.2 (3, 7.4) 0.9 (0.1, 2.5) 75.7 (97.3, 37.7) 1.2 (1.0–1.4)
CMAS (range 0–52) 2 269 27 (13, 36.3) 46 (37, 50) 53.1 (14.3, 155) 1.4 (1.2–1.5)
DAS (range 0–20) 1 273 12 (10, 15) 5 (3, 8) 58.3 (75, 33.3) 1.7 (1.5–1.9)
C-HAQ disability index (0–3) 1 261 1.6 (1, 2.5) 0.3 (0, 1) 75 (100, 25) 1.3 (1.1–1.4)
CHQ physical summary score (range 40–60) 2 211 32.6 (23.7, 42.8) 50.2 (40.8, 54.2) 42.3 (9.2, 84.4) 1.0 (0.9–1.2)
Additional measures
MMT (range 0–80) 2 263 48 (32, 61) 71 (59.5, 78) 36.8 (11.1, 89.6) 1.2 (0.9–1.4)
MYOACT (range 0–10) 1 257 2 (1.1, 3) 0.3 (0.1, 0.8) 83.1 (94.6, 57.4) 1.3 (1.1–1.5)
MITAX (range 0–63) 1 258 17 (9, 25) 2 (1, 5) 84.3 (93.3, 62.5) 1.2 (1.0–1.3)
Physician’s global assessment of extraskeletal
disease activity (0–10-cm scale) 1
271 2.1 (0.4, 5) 0.3 (0, 1.2) 75 (96.1, 0) 0.8 (0.7–0.9)
Physician’s global assessment of muscle
activity (0–10-cm scale) 1
270 5.2 (3.1, 7.6) 0.6 (0, 2.1) 85.2 (100, 50) 1.4 (1.2–1.6)
CHQ psychosocial summary score (range
40–60) 2
211 45.7 (40, 51.9) 49.9 (44.6, 54.8) 6.3 (2.6, 22.3) 0.5 (0.3–0.6)
Parent’s global assessment of child’s pain
(0–10-cm scale) 1
256 3.2 (0.8, 5.9) 0.2 (0, 1.4) 83.1 (100, 8.9) 0.9 (0.7–1.0)
Creatine kinase (0–150 units/liter) 1 263 254 (76, 1,407) 47.4 (21.6, 9) 84.5 (96.8, 21.8) 0.5 (0.4–0.5)
Lactate dehydrogenase (50–150 units/liter) 1 249 239 (167, 414) 138 (106, 180) 43 (65, 15.9) 0.5 (0.3–0.7)
Aldolase (0–6 units/liter) 1 119 11.6 (6.9, 22.3) 4.7 (3.1, 6.9) 60.2 (83.6, 29.4) 0.4 (0.0–0.6)
Aspartate aminotransferase (0–35 units/
liter) 1
248 61.9 (31.5, 135) 22 (15.9, 30) 60.4 (85.1, 28.9) 0.5 (0.4–0.6)
Alanine aminotransferase (0–35 units/liter) 1 256 37.5 (17.5, 80) 16.4 (9.1, 24.5) 61.7 (85.7, 9.6) 0.5 (0.4–0.6)
* Except where indicated otherwise, values are the median (interquartile range). SRM is reported for the subgroup of patients who responded to
treatment according to the physician’s evaluation of response to therapy as an external marker of change (see text for details).1 indicates that a higher
score for that variable denotes worse disease activity;2 indicates that a lower score denotes worse disease activity. IQR  interquartile range; SRM 
standardized response mean; 95% CI  95% confidence interval; CMAS  Childhood Myositis Assessment Scale; DAS  Disease Activity Score;
C-HAQ  Childhood Health Assessment Questionnaire; CHQ  Child Health Questionnaire; MMT  manual muscle strength testing; MYOACT 
Myositis Disease Activity Assessment Visual Analog Scales; MITAX  Myositis Intent-to-Treat Activity Index, A-E version.
† Number of patients for whom both baseline and 6-month evaluations were available.
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sponsiveness, with the exception of the CK whose SRM
was small. An important decrease in responsiveness was
observed when the SRM was calculated in the subgroup of
patients who did not respond to treatment (data not
shown).
Taken together, these results did not show a major ad-
vantage for any of the additional variables over the vari-
ables included in the preliminary core set (16). However,
due to the superior responsiveness to clinically important
change (and minor skewness) demonstrated by the DAS as
compared with the MYOACT and the MITAX, the DAS
was selected for use instead of the 2 latter tools; moreover,
the DAS was the only index that uses the entire range of
possible scores (range 0–20; median score at baseline 12).
Furthermore, since, of the 2 summary scales of the CHQ
(PhS and PsS), only the PhS yielded significant results in
previous analyses, we used only the CHQ PhS as a mea-
sure of health-related quality of life in subsequent evalu-
ations.
Discriminant validity. Figure 1 shows the 6 variables
included in the final core set, which demonstrated signif-
Figure 1. Ability of the variables (mean score changes) included in the core set to discriminate between
patients who improved versus patients who did not improve according to the physician’s and the parent’s
evaluation after 6 months of therapy. Data are presented as box plots, where the squares inside the boxes
represent the mean, and the line outside the boxes the 95% confidence interval. P values refer to the
discriminant ability of the variables according to the physician’s evaluation and to the parent’s evaluation
of response to therapy. MD  physician.
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icant ability (with the exception of the CHQ PhS) in dis-
criminating patients who were improved or not improved
at 6 months based on the physician’s or parent’s assess-
ment of the child’s response to therapy. Other variables
that were able to show a statistically significant discrimi-
nant ability were the MMT, the parents’ rating of child’s
pain, the MITAX (but only for the parent’s evaluation), the
physician’s global assessment of extraskeletal disease ac-
tivity, the physician’s global assessment of muscle activ-
ity, 6 of the 8 subscales of the C-HAQ, and 4 of the 15
subscales of the CHQ (data not shown). All the other
variables, including the muscle enzymes, the MYOACT,
and the MITAX (only for the physician’s evaluation), did
not show significant discriminant validity. Notably, con-
cordance between physicians and parents in the evalua-
tion of response to therapy was substantial (  0.73 [95%
CI 0.63–0.83]).
Construct validity and redundancy. Table 2 shows
Spearman’s correlation coefficients for the baseline-to-6-
month change in the final core set variables. This analysis
was carried out to assess both the construct validity and
the colinearity (or redundancy). As expected, the correla-
tion with the physician’s global assessment of the patient’s
overall disease activity was in the moderate range (r  
0.4 to  0.6) for all variables demonstrating that the final 6
core set variables have good convergent construct validity.
There was no redundancy between the core set variables
(Spearman’s correlation coefficient 0.7), except for the
CMAS and the C-HAQ, which revealed some degree of
colinearity (r  0.71). In spite of this finding, it was
decided to retain both parameters in the core set because it
was felt that they assess largely different constructs, with
the first being a measure of muscle strength and endurance
and the second a measure of functional ability (16). The
high correlation of the CMAs with the MMT (r  0.77), and
their similar responsiveness, suggested that they are inter-
changeable measures of muscle strength.
Internal consistency. As shown in Table 3, assessment
of the baseline values of the 6 variables combined yielded
Table 2. Construct validity for the variables included in the final core set, by Spearman’s correlation matrix*
Variable
Physician’s global





C-HAQ 0.57 0.71 0.52
Parent’s global assessment of
patient’s overall well-
being
0.51 0.56 0.42 0.65
CHQ physical summary
score
0.46 0.61 0.42 0.73 0.58
* Correlations for the absolute change in score (value at month 6 minus value at month 0) were performed and were expected to be in the moderate
range (0.4–0.7). A Spearman’s coefficient of 0.7 was considered to represent evidence of redundancy. CMAS  Childhood Myositis Assessment
Scale; DAS  Disease Activity Score; C-HAQ  Childhood Health Assessment Questionnaire; CHQ  Child Health Questionnaire.
Table 3. Internal consistency of the variables in the final
core set*
Variable Cronbach’s 










CHQ physical summary score 0.56
* Values shown are Cronbach’s alpha when the individual variable
is removed. The performance of the final core set, including all 6
variables, was 0.63. CMAS  Childhood Myositis Assessment
Scale; DAS  Disease Activity Score; C-HAQ  Childhood Health
Assessment Questionnaire; CHQ  Child Health Questionnaire.
Table 4. Logistic regression model to predict

















CMAS 1.2 (0.5–3) 0.71





* Predictions were based on absolute change of the variables in-
cluded in the final core set. Variables were dichotomized according
to the best cutoffs obtained from the receiver operating characteris-
tics (ROC) curve analysis. The area under the ROC curve of the
model was equal to 0.74. The best cutoffs were as follows: for the
physician’s global assessment of patient’s overall disease activity,
 2.4; for the Disease Activity Score (DAS),  5; for the parent’s
global assessment of patient’s overall well-being,  3.7; for the
Childhood Myositis Assessment Scale (CMAS), 5; for the Child-
hood Health Assessment Questionnaire (C-HAQ),  1; for the
Child Health Questionnaire (CHQ) physical summary score, 17.3.
OR  odds ratio; 95% CI  95% confidence interval.
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a Cronbach’s alpha of 0.63, meaning, as expected, that
there was slight internal consistency. When we added the
muscle enzyme CK, Cronbach’s alpha fell to 0.006, sug-
gesting that the inclusion of this measure in the core set
leads to a disruption of its internal consistency.
Association between changes in each of the 6 core set
measures and overall outcome. In the final logistic regres-
sion model (Table 4), the physician’s global assessment of
the patient’s overall disease activity and the DAS appeared
to be the strongest predictors of response to therapy,
whereas the predictive ability of the other 4 variables did
not reach statistical significance. The table also shows the
absolute change cutoffs that should be observed in each
variable of the core set in order to classify the patient as a
responder to a given therapy; for example the 6-month
absolute change in the physician’s global assessment of the
patient’s overall disease activity should be  2.4 on a
scale of 0–10 cm.
Selection of the final core set. Taken together, the re-
sults of the validation analyses showed that the final core
set for the evaluation of response to therapy in juvenile
DM has excellent psychometric properties. Table 5 pre-
sents the 6 domains and the related suggested variables
used to measure each domain that is included in the final
core set. In future studies, it is recommended that the
results for muscle enzymes also be reported, but only for
descriptive purposes.
DISCUSSION
In this report, we present the final validated PRINTO/
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) core set of clinical
measures for the assessment of response to therapy in
patients with juvenile DM assessed through a large, pro-
spective data collection and a comprehensive validation
process that closely mimicked the design of a clinical trial.
The selected variables were shown to be feasible and to
have good construct validity, discriminative ability, and
internal consistency; furthermore, they were not redun-
dant, were responsive to clinically important change, and
they were strongly associated with treatment outcome.
The validation of the core set is a fundamental step in the
process of developing a definition of improvement in ju-
venile DM.
Recently, the IMACS group independently undertook a
similar effort, which led to the development of a core set of
outcome measures and preliminary definitions of im-
provement in adult and juvenile IIM (7,8,32). Although the
overall structure of the PRINTO/ACR/EULAR core set and
IMACS core set domains is remarkably similar (which
ensures convergent validity to the process followed by the
2 networks), there are some important differences. First,
serum muscle enzymes, which are part of the IMACS core
set and were included in the preliminary PRINTO/ACR/
EULAR core set (16), have been removed from the final
PRINTO/ACR/EULAR core set as a result of their poor
statistical performance in the validation analyses (see be-
low). Second, health-related quality of life assessment has
been selected as a distinct core set domain by the PRINTO/
ACR/EULAR group, whereas the IMACS investigators did
not incorporate it in the core set, although they recom-
mended this measure be included in therapeutic trials of
patients with IIM. The PRINTO/ACR/EULAR core set is
given a unique strength by the validation process reported
herein, which enabled the evidence-based scrutiny and
selection of the candidate variables through the analysis of
a large, prospectively collected patient sample.
The PRINTO/ACR/EULAR core set was designed to be
robust enough to cover all disease phenotypes of juvenile
DM, focusing on the central features of the physician’s
subjective estimation of the level of disease activity, mus-
cle strength, global disease activity scoring, parent’s global
assessment of the patient’s overall well-being, functional
ability, and the health-related quality of life. It should be
kept in mind, however, that the recommended variables
are not more than a minimal core set, and that investiga-
tors can measure as many other variables as they deem
appropriate for the major hypothesis that is being tested.
In recent years, there has been increasing collaborative
effort to pool expertise in order to devise composite activ-
ity indices for a standardized clinical assessment of juve-
nile DM (5,6). Two global disease activity measures for
juvenile DM are currently available, the DAS (31) and the
MDAA (32). Compared with the MDAA, the DAS revealed
superior responsiveness to clinically important change,
minor skewness, and better ability to use the entire range
of possible scores and for these reasons, was included in
the core set.
Evaluation of the extent and severity of muscle inflam-
mation is of major importance in assessing disease activity
and response to therapy in juvenile DM patients. Muscle
strength is the primary clinical measure used to assess
muscle disease. The MMT (23) is the most widely used
method for muscle strength measurement in therapeutic
trials; however, the most popular muscle function tool in
Table 5. Domains and suggested variables included in
the final core set for the evaluation of response to
therapy in juvenile DM*
Domain Suggested variable(s)
Physician’s global assessment
of patient’s overall disease
activity
10-cm VAS
Muscle strength CMAS (or MMT)
Global juvenile DM disease
activity tool
DAS (or MYOACT or
MITAX)
Parent’s global assessment of
patient’s overall well-being
10-cm VAS
Functional ability assessment C-HAQ




* Juvenile DM  juvenile dermatomyositis; VAS  visual analog
scale; CMAS  Childhood Myositis Assessment Scale; MMT 
manual muscle testing; DAS  Disease Activity Score; MYOACT 
Myositis Disease Activity Assessment Visual Analog Scales; MITAX
 Myositis Intent-to-Treat Activity Index, A-E version; C-HAQ 
Childhood Health Assessment Questionnaire; CHQ  Child Health
Questionnaire.
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children with juvenile DM is the CMAS (20–22), which
evaluates a combination of muscle strength, muscle func-
tion, and endurance. We found that the MMT and CMAS
had similar responsiveness and a certain degree of redun-
dancy. The latter finding led us to suggest that the 2 tools
can be used interchangeably for the evaluation of muscle
strength. Potential advantages of the MMT are its brevity
and forwardness, whereas the CMAS may be easier to use
with younger children. The good statistical performances
yielded by the measure of physical function (the C-HAQ)
are in keeping with those obtained in previous studies in
juvenile DM patients (45). Keeping with the results of the
initial consensus conference (16) the final PRINTO/ACR/
EULAR core set maintained the distinction between the
measures to evaluate muscle strength (CMAS or MMT) and
functional ability (by C-HAQ) despite a certain degree of
redundancy between the 3 tools. This distinction is an-
other difference from the IMACS core set where only the
MMT is presented as a measure of muscle strength while
the CMAS or the C-HAQ are presented as measures of
functional ability.
The measurement of serum levels of muscle-derived
enzymes has long been used as an indicator of myositis
activity in the clinical management of patients with juve-
nile DM. High levels of enzymes may help to differentiate
active disease from disease remission or muscle damage,
in which their levels are usually normal or near normal.
However, it is well known that many patients have no
muscle enzyme elevation at the time of diagnosis (24–28).
Furthermore, CK levels and other muscle enzymes often
do not correlate with measures of muscle strength, with
CK levels improving without a correspondent improve-
ment in muscle function. The imperfect correlation of
serum muscle enzymes with myositis activity was con-
firmed in our analyses, which revealed that all enzymes
were only moderately or poorly responsive to change in
disease activity over time. Furthermore, the inclusion of
CK levels into the core set of variables led to a marked
decrease in internal consistency. For this reason, it was
decided to exclude serum muscle enzymes from the final
core set.
Health-related quality of life has been increasingly rec-
ognized as an important domain to be included in thera-
peutic trials and observational studies of patients with
juvenile DM because it addresses aspects of disease that
are not fully captured by other endpoints (5,6). Therefore,
the assessment of health-related quality of life was incor-
porated in the juvenile DM core set as a separate domain.
We found that the physical scale of the CHQ had better
evaluative properties than the psychosocial scale, which
may be partially explained by the observation that patients
with juvenile DM have greater impairment in physical
than in psychosocial well-being (46).
Our study has certain limitations, which include the fact
that it was not conducted in the context of a real clinical
trial, and that the use of corticosteroids or immunosup-
pressive drugs as intervention therapy was not standard-
ized and might have led to changes in the level of disease
activity much greater than those that would be expected in
trials of novel immunosuppressive or biologic agents. We
did not investigate the role of imaging modalities (i.e.,
magnetic resonance imaging [47–49] or muscle ultra-
sound) both of which are increasingly used to assess mus-
cle disease activity; however, the magnetic resonance im-
aging is costly and not readily available in many centers,
and muscle ultrasound has not yet been sufficiently stan-
dardized. Moreover, the use of somewhat similar dimen-
sions for the evaluation of the physician’s global assess-
ment of disease activity and physician’s evaluation of
response to therapy might have introduced some bias de-
spite the required separation between the role of the 2
physicians. The main strength of the study is the large
amount of prospectively collected data, which ensured an
evidence-based initial validation analysis. To our knowl-
edge, this is the first time that clinical measures of juvenile
DM have been tested longitudinally for their statistical
performance, individually and as a group.
In conclusion, we have presented the validated
PRINTO/ACR/EULAR core set of outcome domains for the
evaluation of response to therapy in juvenile DM, which
will constitute the basis for creating a definition of im-
provement to be used in randomized clinical trials. This
will allow improved assessment of efficacy of new thera-
peutic agents or regimens, with greater validity and com-
prehensiveness.
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